KPV 500mcg 100pcs Oral steroids tablets

Description

KPV 500mcg Oral Anti-Inflammatory Tripeptide Research

About This Compound

KPV (Lysine-Proline-Valine) is a naturally occurring tripeptide that constitutes the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). This signaling molecule serves as a primary research benchmark for investigating the targeted modulation of immune responses and the suppression of systemic inflammation. [KPV regulates inflammatory cytokine cascades]. By specifically targeting cellular inflammatory pathways without typical immunosuppressive drawbacks, it provides a high-fidelity model for evaluating mucosal integrity and tissue homeostasis.

Molecular Data

• CAS Number: 18465-30-0
• Molecular Formula: C16H30N4O4
• Molecular Weight: 342.43 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Mechanism Overview

The biochemical activity of KPV is defined by its ability to modulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway. Initially, the highly permeable tripeptide enters the target cell or binds to surface melanocortin-1 receptors (MC1R). This defines the first semantic triple: [KPV agonizes melanocortin-1 receptors]. Additionally, this intracellular interaction directly inhibits the translocation of NF-kB into the nucleus. This establishes the second triple: [KPV inhibits NF-kB nuclear translocation]. Thirdly, the blockade of this transcription factor halts the downstream production of pro-inflammatory cytokines such as TNF-alpha and IL-6. This forms the third triple: [NF-kB suppression reduces pro-inflammatory cytokines]. Quantitatively, the KPV tripeptide exhibits a relatively short systemic half-life of approximately 2 hours ($t_{1/2}=2.0pm0.5$h) in mammalian models, requiring sustained or targeted delivery systems. In comparative studies, KPV is distinguished from full-length alpha-MSH or Melanotan 1 Acetate by its complete lack of melanotropic activity; it provides potent anti-inflammatory signaling without inducing melanin synthesis or skin pigmentation.

Known Effects

• Gastrointestinal Mucosal Support: Users report significant improvements in gut barrier integrity and the reduction of localized inflammatory markers in research models.
• Systemic Inflammation Reduction: Experimental findings suggest a marked decrease in chronic inflammatory states and joint discomfort.
• Mast Cell Stabilization: Based on community feedback, research models show a reduction in histamine-related responses and improved mast cell homeostasis.
• Dermatological Resilience: Cumulative findings indicate accelerated recovery from skin irritation when studied alongside systemic immune modulators.
• Non-Immunosuppressive Action: Research models have observed that unlike corticosteroids, KPV reduces inflammation without globally suppressing the adaptive immune system.

Summary:
KPV 500mcg Oral represents a highly targeted, non-hormonal research tool for investigating the precise molecular inhibition of the NF-kB pathway and localized mucosal inflammation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.